Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents

References

• Janczyk W, Socha P, Lebensztejn D et al. Omega-3 fatty acids for treatment of non alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr. 13, 85–94 (2013).
   Google Scholar
• Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 56, 944–951 (2012).
   Google Scholar
• Nobili V, Bedogni G, Alisi A et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch. Dis. Child. 96(4), 350–353 (2011). ▪ Large study with omega‑3 adminstration in children with nonalcoholic fatty liver disease (NAFLD).
   Google Scholar
• Lee JH, O’Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. Mayo Clin. Proc. 83, 324–332 (2008).
   Google Scholar
• Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin. Cardiol. 32(7), 365–372 (2009).
   Google Scholar
• Bernstein AM, Ding EL, Willett WC, Rimm EB. A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDLcholesterol and LDL-cholesterol in persons without coronary heart disease. J. Nutr. 142(1), 99–104 (2012).
   Google Scholar
• Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. Br. J. Nutr. 107(Suppl. 2), S159–S170 (2012).
   Google Scholar
• Klein-Platat C, Drai J, Oujaa M, Schlienger JL, Simon C. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am. J. Clin. Nutr. 82(6), 1178–1184 (2005).
   Google Scholar
• Ovchinsky N, Lavine JE. A critical appraisal of advances in pediatric nonalcoholic fatty liver disease. Semin. Liver Dis. 32(4), 317–324 (2012).
   Google Scholar
• Mencin AA, Lavine JE. Nonalcoholic fatty liver disease in children. Curr. Opin. Clin. Nutr. Metab. Care 14(2), 151–157 (2011). ▪ Analysis of advancements in genetics, pathophysiology and the treatment of NAFLD, with an emphasis on recent developments in the field.
   Google Scholar
• Schwimmer JB, Dunn W, Norman GJ et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 138, 1357–1364 (2010).
   Google Scholar
• Manco M, Marcellini M, Devito R et al. Metabolic syndrome and liver histology in paediatric nonalcoholic steatohepatitis. Int. J. Obes. (Lond.) 32, 381–387 (2008).
   Google Scholar
• St-Jules DE, Watters CA, Brunt EM et al.; for the NASH CRN. Estimation of fish and omega-3 fatty acid intake in pediatric nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. doi:10.1097/ MPG.0b013e3182a1df77 (2013) (Epub ahead of print).
   Google Scholar
• Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis. 10, 49–54 (2011).
   Google Scholar
• Alkhouri N, Sedki E, Alisi A et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 33(1), 79–85 (2013).
   Google Scholar
• Athyros VG, Tziomalos K, Gossios TD et al. GREACE Study Collaborative Group: safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 376, 1916–1922 (2010). ▪▪ First prospective study with biopsy‑proven NAFLD that showed complete resolution of NAFLD within 1 year of treatment.
   Google Scholar
• Athyros VG, Giouleme O, Ganotakis ES et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch. Med. Sci. 7(5), 796–805 (2011). ▪ First prospective study with improvement of NAFLD with statins.
   Google Scholar
• Kargiotis K, Katsiki N, Athyros VG et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia. A preliminary report. Curr. Vasc. Pharmacol. (2013) (In Press).
   Google Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr. Med. Res. Opin. 22(5), 873–883 (2006).
   Google Scholar
• Kiyici M, Gulten M, Gurel S et al. Ursodeoxycholic acid and atorvastatin in the treatment of non-alcoholic steatohepatitis. Can. J. Gastroenterol. 17(12), 713–718 (2003).
   Google Scholar
• Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol. 47(1), 135–141 (2007).
   Google Scholar